Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.

Neuro-oncology - 3 Jun 2024

Arrillaga-Romany Isabel, Miller Julie J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Glioma
Share to Histones

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38588460
DOI: 10.1093/neuonc/noae051
PMCID: PMC11145450

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.PMID 38588460Read ↗

Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline gliomaSemantic proximity Read ↗

New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline GliomaSemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.Semantic proximity Read ↗

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read ↗

H3G34-Mutant Gliomas—A Review of Molecular Pathogenesis and Therapeutic OptionsSemantic proximity Read ↗

H3K27-Altered Diffuse Midline Glioma of the Brainstem: From Molecular Mechanisms to Targeted Interventions.Semantic proximity Read ↗

H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.Semantic proximity Read ↗

Diffuse midline gliomas with subclonal H3F3A K27M mutation and mosaic H3.3 K27M mutant protein expression.Semantic proximity Read ↗

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations.Semantic proximity Read ↗

Survival analysis of adult midline-located gliomas and diffuse midline gliomas: beyond the H3K27 mutation paradigm.Semantic proximity Read ↗

Radiotherapy and radio-sensitization in H3K27M -mutated diffuse midline gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.